At a glance
ClinicalIndex Comparison RecordN/ACompleted· 69 enrolled
Drug / intervention
Herceptin (Trastuzumab)drug
Likely dose
Herceptin (Trastuzumab) 8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast
In Brief
A clinical study evaluating Herceptin (Trastuzumab) for Ductal Carcinoma In Situ. Completed, enrolled 69 participants across 1 site.
Detailed Summary
Primary Objectives: * To determine the effect of a single dose of Herceptin (trastuzumab) on the proliferation rate of Her-2/neu over-expressing ductal carcinoma in situ (DCIS) * To evaluate the effect of a single dose of Herceptin on the apoptotic index of Her-2/neu over-expressing DCIS
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDuctal Carcinoma In Situ
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2005
First PostedJul 2007
Primary CompletionNov 2010
TodayJul 2026
First PostedJul 4, 2007
Enrollment StartMar 1, 2005
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 19.0 years ago
Interventions
Herceptin (Trastuzumab)drug
8 mg/kg IV Over 90 Minutes